Correction to: Extended duration of treatment using reduced‑frequency dosing of anti‑PD‑1 therapy in patients with advanced melanoma and Merkel cell carcinoma (Cancer Immunology, Immunotherapy, (2023), 72, 11, (3839-3850), 10.1007/s00262-023-03539-8)

Lisa May Ling Tachiki*, Daniel S. Hippe, Karly Williams Silva, Evan Thomas Hall, William McCamy, Dane Fritzsche, Andrea Perdue, Julia Majovski, Thomas Pulliam, Daniel A. Goldstein, Joshua Veatch, Joel Ho, Paul T. Nghiem, John A. Thompson, Shailender Bhatia*

*Corresponding author for this work

Research output: Contribution to journalComment/debate

Abstract

The original version of this article unfortunately contained a mistake. The corrected detail is provided below: In discussion section, 6th sentence of the 10th paragraph which previously read: In future trials, tests such as clinical biopsy or ctDNA could be used to identify patients with residual disease that may benefit extended duration of treatment with RFD. Should read: In future trials, tests such as clinical biopsy or ctDNA could be used to identify patients with residual disease that may benefit from extended duration of treatment with RFD.

Original languageEnglish
Pages (from-to)4471
Number of pages1
JournalCancer Immunology, Immunotherapy
Volume72
Issue number12
DOIs
StatePublished - Dec 2023
Externally publishedYes

Fingerprint

Dive into the research topics of 'Correction to: Extended duration of treatment using reduced‑frequency dosing of anti‑PD‑1 therapy in patients with advanced melanoma and Merkel cell carcinoma (Cancer Immunology, Immunotherapy, (2023), 72, 11, (3839-3850), 10.1007/s00262-023-03539-8)'. Together they form a unique fingerprint.

Cite this